EGFR and non-small cell lung carcinoma: The results showed that neither ICIs nor combination therapy prolonged median OS in EGFR-TKI resistant NSCLC patients (HR = 1.04, 95% CI: 0.84-1.29, <i>p</i> = 0.73).